Novanta has agreed to acquire Riverpoint Medical for up to $1.45 billion to strengthen its position in the medical consumables market and enter the minimally invasive surgery segment.
The deal includes $1.2 billion upfront in cash plus a potential $250 million milestone payment expected in 2027. The acquisition is planned to close in Q3 2026.
Related: Olympus agrees $270M BioProtect buyout to expand prostate cancer offerings
Riverpoint Medical develops advanced surgical fibers, instruments, and private-label minimally invasive surgical products for areas including sports medicine, trauma, and cardiovascular surgery. The company will become part of Novanta’s medical solutions business.
Novanta said the acquisition supports its strategy of increasing recurring revenue and reducing business volatility. CEO Matthijs Glastra said:
“Together with Novanta’s core business, this acquisition is projected to double our recurring medical consumables revenue to approximately $300m, deepen our medical end-market concentration to 60% of total revenue, and meaningfully accelerate revenue and profit growth.”
The transaction marks a major move for Novanta to expand its medical technology footprint and strengthen long-term growth in surgical markets.
